IL106981A - Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity - Google Patents

Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity

Info

Publication number
IL106981A
IL106981A IL10698193A IL10698193A IL106981A IL 106981 A IL106981 A IL 106981A IL 10698193 A IL10698193 A IL 10698193A IL 10698193 A IL10698193 A IL 10698193A IL 106981 A IL106981 A IL 106981A
Authority
IL
Israel
Prior art keywords
thrombin inhibitor
direct
manufacture
acting thrombin
thrombolytic activity
Prior art date
Application number
IL10698193A
Other languages
English (en)
Hebrew (he)
Other versions
IL106981A0 (en
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo filed Critical Synthelabo
Publication of IL106981A0 publication Critical patent/IL106981A0/xx
Publication of IL106981A publication Critical patent/IL106981A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL10698193A 1992-09-11 1993-09-10 Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity IL106981A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9210833A FR2695562B1 (fr) 1992-09-11 1992-09-11 Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique.

Publications (2)

Publication Number Publication Date
IL106981A0 IL106981A0 (en) 1993-12-28
IL106981A true IL106981A (en) 1999-03-12

Family

ID=9433400

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10698193A IL106981A (en) 1992-09-11 1993-09-10 Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity

Country Status (18)

Country Link
US (1) US5583113A (xx)
EP (1) EP0589741B1 (xx)
JP (1) JPH06228007A (xx)
KR (1) KR100261526B1 (xx)
CN (1) CN1066961C (xx)
AT (1) ATE163856T1 (xx)
AU (1) AU4628193A (xx)
CA (1) CA2105888C (xx)
CZ (1) CZ188893A3 (xx)
DE (1) DE69317343T2 (xx)
DK (1) DK0589741T3 (xx)
ES (1) ES2115741T4 (xx)
FR (1) FR2695562B1 (xx)
IL (1) IL106981A (xx)
NO (1) NO306537B1 (xx)
SK (1) SK96993A3 (xx)
TW (1) TW284691B (xx)
ZA (1) ZA936707B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830448A (en) * 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
MX9706069A (es) * 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
IL136139A0 (en) 1998-01-26 2001-05-20 Basf Ag Thrombin inhibitors
CN101598725B (zh) * 2009-06-23 2012-07-18 南通大学附属医院 阿加曲班在血细胞和生化常规分析中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258192A (en) * 1977-12-16 1981-03-24 Mitsubishi Chemical Industries Limited N2 -Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US4318904A (en) * 1980-04-25 1982-03-09 Research Corporation Peptide affinity labels for thrombin and other trypsin-like proteases
US4929602A (en) * 1987-11-25 1990-05-29 Scripps Clinic And Research Foundation Method of inhibiting platelet dependent arterial thrombosis
US5196404B1 (en) * 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin

Also Published As

Publication number Publication date
CA2105888A1 (fr) 1994-03-12
NO933235D0 (no) 1993-09-10
CA2105888C (fr) 2008-04-15
FR2695562A1 (fr) 1994-03-18
CN1066961C (zh) 2001-06-13
IL106981A0 (en) 1993-12-28
NO306537B1 (no) 1999-11-22
JPH06228007A (ja) 1994-08-16
AU4628193A (en) 1994-03-17
ES2115741T4 (es) 2012-07-04
ATE163856T1 (de) 1998-03-15
US5583113A (en) 1996-12-10
NO933235L (no) 1994-03-14
ES2115741T3 (es) 1998-07-01
CN1087015A (zh) 1994-05-25
KR100261526B1 (ko) 2000-07-15
EP0589741A1 (fr) 1994-03-30
TW284691B (xx) 1996-09-01
DK0589741T3 (da) 1998-12-21
ZA936707B (en) 1994-03-30
FR2695562B1 (fr) 1994-10-14
SK96993A3 (en) 1994-08-10
DE69317343T2 (de) 1998-10-08
KR940006600A (ko) 1994-04-25
DE69317343D1 (de) 1998-04-16
CZ188893A3 (en) 1994-03-16
EP0589741B1 (fr) 1998-03-11

Similar Documents

Publication Publication Date Title
Lidon et al. Initial experience with a direct antithrombin, Hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects.
DE69503120T2 (de) Zusammensetzungen aus einer thrombolytisch wirkende substanz und antikoagulantien, und ihre verwendungen
US6235279B1 (en) Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins
IL106981A (en) Use of active-direct thrombin monitoring for the production of medical products that have thrombolytic activity
Weiss et al. Effect of aspirin and dipyridamole on the interaction of human platelets with sub-endothelium: studies using citrated and native blood
US5055295A (en) Lysis of fibrin blood clots with urokinase and pro-urokinase
Sobel et al. Coronary thrombolysis with facilitated absorption of intramuscularly injected tissue-type plasminogen activator.
Bode et al. Absence of drug interaction between heparin and nitroglycerin: randomized placebo-controlled crossover study
Spivey et al. Plasma catecholamine levels after intraosseous epinephrine administration in a cardiac arrest model
Kurz et al. Effects of intracoronary low-dose enalaprilat as an adjunct to primary percutaneous transluminal coronary angiography in acute myocardial infarction
Kerins et al. Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue.
Werns et al. Nitroglycerin inhibits experimental thrombosis and reocclusion after thrombolysis
Hanson et al. Effect of dazoxiben on arterial graft thrombosis in the baboon.
EP0265129A1 (en) Thrombolytic therapy
Dembińska-Kieć et al. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans
EP0223192B1 (en) Pharmaceutical composition having thrombolytic activity
US3790672A (en) Method for activating blood fibrinolysis by administration of a salt of 2-amino-ethanesulphonic acid
CA2025661A1 (en) Method of improving post-ischemic myocardial function using a thromboxane a antagonist in combination with a thrombolytic agent and combination
Kostka-Trabkowa et al. Beneficial results of pentoxifylline (‘Trenta’) therapy in arteriosclerosis obliterans: possible mechanism of action
Saito et al. A novel modified tissue-type plasminogen activator (t-PA), E6010, gradually increases coronary blood flow after thrombolysis compared with native t-PA, urokinase and balloon catheter occlusion-reperfusion
Schaub Ciprostene, a stable prostacyclin analog, produces peripheral vasodilation, platelet inhibition and increased clot dissolution in the cat
EP3311812A1 (en) COMBINATION OF TAFIa INHIBITOR WITH PLASMINOGEN ACTIVATOR
Li et al. Inhibition of vasoconstrictor mechanisms by dazoxiben in the rat mesenteric vasculature
Ohyanagi et al. Extended use of fluosol emulsion in acute myocardial ischemia treatment
GB2197195A (en) Urokinase compositions for treating thrombosis

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
RH1 Patent not in force